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Candida albicans forms oral bioﬁlms that cause disease and are difﬁcult to treat with
conventional antifungal agents. Tea tree oil (TTO) is a natural compound with reported
antimicrobial and immunomodulatory activities.The aims of the study were to evaluate the
antifungal efﬁcacy of TTO and key derivatives against C. albicans bioﬁlms, to assess the
toxicological effects ofTTO on a clinically relevant oral cell line, and to investigate its impact
on inﬂammation.TTO and its derivatives were examined against 100 clinical strains of C.
albicans. Planktonic minimum inhibitory concentrations (MICs) were determined using the
CLSI M-27A broth microdilution method. Sessile MICs were determined using an XTT
reduction assay. Inhibition, time-kill, and mode of action studies were performed. OKF6-
TERT2epithelialcellswereusedforcytotoxicityandcytokineexpressionassays.Planktonic
C. albicans isolates were susceptible toTTO, terpinen-4-ol (T-4-ol), and a-terpineol, with an
MIC50 of 0.5, 0.25, and 0.25%, respectively.These three compounds also displayed potent
activityagainstthe69bioﬁlm-formingstrains,ofwhichT-4-oland a-terpineoldisplayedrapid
kill kinetics. For all three compounds, 1MIC50 effectively inhibited bioﬁlm growth when
C. albicans were treated at 0, 1, and 2h post adhesion. By scanning electron microscopy
analysis and PI uptake,TTO and derivative components were shown to be cell membrane
active.TTO andT-4-ol were cytotoxic at 1MIC50, whereas at 0.5MIC50T-4-ol displayed
no signiﬁcant toxicity. Transcript and protein analysis showed a reduction of IL-8 when
treated with TTO and T-4-ol. These data provide further in vitro evidence that TTO and its
derivative components, speciﬁcally T-4-ol, exhibit strong antimicrobial properties against
fungal bioﬁlms. T-4-ol has safety advantages over the complete essential oil and may be
suitable for prophylaxis and treatment of established oropharyngeal candidosis. A clinical
trial ofT-4-ol is worthy of consideration.
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INTRODUCTION
Many cancer therapies have a profound negative impact on
oral health, causing serious complications (Dreizen, 1990). These
include both non-infectious and infectious side-effects with
potential for systemic spread (Wingard, 1990). Oral fungal infec-
tions, caused predominantly by Candida species, are common in
patients suffering from cancer at all stages of the disease, espe-
cially those receiving palliative care (Sweeney et al.,1998;Sweeney
and Bagg, 2000; Davies et al., 2006). Candida albicans is known
to form complex bioﬁlms (Ramage et al., 2005; Ganguly and
Mitchell, 2011) and other Candida spp. also have this ability to
varying degrees, though it is strain-dependent (Silva et al., 2009).
Such bioﬁlms form on the oral epithelium or on the surfaces
of intra-oral prostheses (Williams et al., 2011), and can result in
pseudomembranous or erythematous candidosis.
The effectiveness of most antifungal agents is signiﬁcantly
reduced if yeasts are in a bioﬁlm as opposed to the planktonic
state (Kuhn and Ghannoum, 2004; Lamfon et al., 2004; d’Enfert,
2006). Furthermore, in recent years there has been growing con-
cernabouttheincreasingprevalenceof infectionscausedbyyeasts
that are resistant to commonly used antifungal drugs (Bagg et al.,
2003), with the emergence of strains of C. albicans that are resis-
tant tothe azole antifungals (Casalinuovoet al.,2004),in addition
totheinherentlyreduceddrugsusceptibilityofmanynon-albicans
yeasts that can be selected through over-use of antifungal drugs
(Davies et al., 2002; Bagg et al., 2003). There is a need to identify
new methods of preventing and treating oral candidosis among
immunocompromised patients,including those with cancer,both
toimprovetreatmentof establishedinfectionsandtolimitfurther
development of drug resistance. Given the extensive evolutionary
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interaction that exists between plants and microorganisms it is
unlikely that resistance would be cause for concern, neverthe-
less,clinicallywewouldanticipatenaturalcompoundstoaugment
existing antifungal agents opposed to direct replacement.
One agent which merits consideration is tea tree oil (TTO;
Hartford and Zug, 2005; Carson et al., 2006), which has recently
reported to have minimal impact on developing resistance (Ham-
mer et al., 2012). TTO is produced as a distillate of leaves of the
Melaleuca alternifolia shrub, which grows in New South Wales,
Australia. It is a complex mixture of essential oils, comprising
approximately100components,mostof whicharemonoterpenes,
sesquiterpenes, and their related alcohols (Carson et al., 2006).
TTO has been shown to possess a number of therapeutic prop-
erties, including anti-inﬂammatory activities (Hart et al., 2000;
Koh et al., 2002; Pearce et al., 2005) and there is current inter-
est in its possible anti-tumor properties (Bozzuto et al., 2011).
However, it is best known for its antimicrobial activity against
a wide spectrum of microorganisms, for example Staphylococcus
aureus (includingMRSA;Thompsonetal.,2008;Kwiecinskietal.,
2009),arangeof oralbacteria(Hammeretal.,2003b),andcertain
viruses, including herpes simplex and inﬂuenza viruses (Carson
et al., 2001; Garozzo et al., 2011). TTO also has potent activ-
ity against many fungi (Hammer et al., 2003a, 2004), including
some azole-resistant yeasts (Mondello et al., 2003; Bagg et al.,
2006) and there is some evidence for its efﬁcacy in treating ﬂu-
conazole refractory oral candidosis in AIDS patients. This raises
the possibility of using TTO preparations for the prevention and
treatment of oral candidal infections. Oral care products are now
availablecontainingTTO(SoukoulisandHirsch,2004),including
an alcohol-free mouthwash. However, hypersensitivity reactions
to TTO have been reported (Knight and Hausen, 1994; Mozelsio
et al., 2003; Hammer et al., 2006; Rutherford et al., 2007) and the
palatability of the agent as an oral preparation is poor. Moreover,
given the complex chemical composition of TTO,which results in
batch-to-batch variability, then the ability to accurately interpret
its clinical utility is limited. Some of the individual components
of TTO are believed to have antimicrobial properties (Mondello
et al., 2006) and may be more appropriate for development into
oral care products with respect to safety and consistency.
This study had three aims. The ﬁrst was to evaluate the efﬁcacy
of TTO and two of its key derivatives [terpinen-4-ol (T-4-ol) and
a-terpineol] against bioﬁlms formed by a clinically diverse panel
of C. albicans isolates. Secondly, the toxicological effects of TTO
and derivative components were assessed by means of a clinically
relevantoralcellline.Finally,thestudyaimedtoinvestigatefurther
the previously reported anti-inﬂammatory effects of TTO.
MATERIALS AND METHODS
STRAINS AND GROWTH CONDITIONS
One-hundredclinicalstrainsof C.albicans wereusedinthecourse
of this study, which were isolated from a wide variety of patient
groups, including those with denture stomatitis (Glasgow Den-
tal School, n D26), those receiving palliative care for advanced
cancer (Accord Hospice, Paisley, n D30), neonates (Royal Hos-
pital for Sick Children, Glasgow, n D36), and those with blood-
stream infections (Glasgow Royal Inﬁrmary, n D8). All strains
were maintained routinely on Sabouraud dextrose (SAB) agar
(Oxoid, Basingstoke, UK) stored at 4˚C, and stored indeﬁnitely
on Microbank beads (Prolab Diagnostics) at  80˚C.
ANTIFUNGAL COMPOUNDS
Tea tree oil and seven HPLC-grade derivatives of the oil obtained
from Sigma-Aldrich (Poole, Dorset) were used in the study.
The derivatives included terpinen-4-ol (T-4-ol), a-terpineol, 1-
8-cineole, terpinolene, a-terpinene, g-terpinene, and p-cymene.
Stock concentrations of each component were prepared in RPMI-
1640 AutoMod™ medium (Sigma, UK), containing 0.5% (v/v)
Tween® 80 (ICI Americas,Inc.). Each compound was prepared as
a 4% v/v solution for testing and serially diluted for both plank-
tonic and sessile susceptibility testing.All procedures were carried
out in a laminar ﬂow cabinet (Hera Safe laminar ﬂow cabinet,
Kendro, Model K515).
SUSCEPTIBILITY TESTING AND BIOFILM INHIBITION
Antifungal testing to determine planktonic minimum inhibitory
concentrations (PMICs) was performed using the CLSI M-
27A broth microdilution method (Clinical Laboratory Standards
Institute, 2008). For sessile susceptibility testing, C. albicans
bioﬁlms were formed as previously described on polystyrene,
ﬂat-bottomed, 96-well microtiter plates (Corning Incorporated,
Corning, NY, USA; Ramage et al., 2001). These were treated with
a range of concentrations of each antifungal compound (0.0625–
2%)inRPMI-1640containing0.5%(v/v)TWEEN80®.After24h
challengethesessileminimumfungicidalconcentrations(SMFCs)
were determined as a 50% inhibition compared to the untreated
control using a XTT reduction assay, as described previously
(Ramage et al., 2001). For time-kill studies C. albicans bioﬁlms
(n D3) were grown for 24h, then exposed to TTO, T-4-ol, or a-
terpineol at a concentration of 2MIC90 for 2,5,15,and 60min.
Metabolic activity was quantiﬁed by the XTT assay and bioﬁlm
viability assessed as a relative reduction in absorbance in com-
parison to untreated controls. For inhibition, C. albicans isolates
(n D4) were plated in 96-well microtiter plates for bioﬁlm growth
(1106 cells/ml) then treated at 0,1,2,or 4h after adhesion with
TTO,T-4-ol,and a-terpineol at 0.5 and 1MIC50. The cells were
then incubated for a further 24h at 37˚C. The levels of bioﬁlm
inhibition were compared to an untreated control using a crys-
tal violet biomass assay, as previously described (Mowat et al.,
2007). All experiments outlined above were performed on two
independent occasions with a minimum of three clinical isolates
in triplicate.
MODE OF ACTION
We investigated whether TTO or T-4-ol interacted with the mem-
brane using a propidium iodide (PI) uptake assay, as previously
reported (Sherry et al., 2012). PI is a ﬂuorescent dye that dif-
fuses through the membranes of dead cells and is incorporated
withinnuclearDNA,thereforeincreasedﬂuorescencedirectlycor-
relates with reduced membrane integrity. C. albicans (3153A) was
grown in an overnight broth as described previously, and stan-
dardized to 1107 cells/ml in RPMI-1640 and treated with TTO,
T-4-ol, or a-terpineol at a concentration of 2MIC50 for 10,
20, 30, 40, 50, and 60min. Following treatment, cells were cen-
trifuged at 10,000rpm to remove the compounds, washed with
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PBS,stained with 20mM of propidium iodide (PI;Sigma-Aldrich,
UK),and incubated at 37˚C for 15min to allow the dye to bind to
DNA. One-hundred microliters of each sample were transferred
to a black microtiter plate (Corning Incorporated, NY, USA) and
ﬂuorescence measured using a microtiter plate reader (FluoStar
Omega, BMG Labtech) at excitation and emission wavelengths
535/617nm,respectively.Rawdatawerecorrectedforbackground
ﬂuorescenceandtheassaywascarriedoutintriplicate.Inaddition,
the physical effect of these compounds was assessed microscopi-
cally using scanning electron microscopy (SEM). C. albicans was
adheredtoThermanox™coverslips(NuncInc.,ThermoFisherSci-
entiﬁc) for 2h within 24 well tissue culture plates then treated
with TTO and T-4-ol at 2MIC50 for 24h. The cells were ﬁxed
using 2% w/v para-formaldehyde, 2% v/v glutaraldehyde, 0.15M
sodium cacodylate, and 0.15% Alcian Blue (pH 7.4), and pre-
paredforSEMaspreviouslydescribed(Erlandsenetal.,2004).The
ﬁxedanddriedbioﬁlmsamplesweresputter-coatedwithgoldand
viewed under a JEOL JSM-6400 scanning electron microscope.
ORAL EPITHELIAL CELL LINE
OKF6-TERT2 epithelial cells were used as previously described
(Ramage et al., 2012). This is an immortalized human oral ker-
atinocytecelllineprovidedbytheRheinwaldLaboratory(Brigham
and Woman’s Hospital, Boston). These cells were immortalized
by forced expression of telomerase, and resemble primary oral
keratinocytes in studies of cytotoxicity or inducible cytokine
and beta-defensin expression (Dongari-Bagtzoglou and Kashleva,
2003).Thecellswereculturedinkeratinocyteserum-freemedium
(KSFM) supplemented with 100IU penicillin,100mg/ml strepto-
mycin,25mg/ml bovine pituitary extract (BPE),0.2ng/ml epider-
malgrowthfactor(EGF),and0.3mMCaCl2 (0.4mMtotalCa2C).
Primaryperiradicularﬁbroblasts(PRF,kindgiftofProfessorColin
Murray, University of Glasgow) were cultured in standard Dul-
becco’s Modiﬁed Eagles Medium (DMEM) with 10% fetal calf
serum(FCS),2mMl-glutamine,100IUpenicillin,and100mg/ml
streptomycin. Both cell lines were passaged at approximately 90%
conﬂuence, using 0.05% Trypsin EDTA. Experiments were used
with cells between passages 5 and 10.
TOXICITY STUDIES
TTO and T-4-ol dilutions were prepared in KSFM or DMEM
with 0.25% (v/v) Tween® 80 for OKF6 or PRF cells, respec-
tively. To assess cytotoxicity, cells were seeded at 1105 cells
per well per ml in KSFM or DMEM in a 24 well culture
plate and grown until 90–100% conﬂuent. Medium was then
removed and cells exposed to 0.5 and 1MIC50 of each com-
pound for 2min, then cells were washed gently (3) in Hanks
balanced salt solution. The viability of the cells was assessed
using an XTT assay (0.25mg/ml XTT and 1mM of menadione
in KSFM or DMEM), in which the cells were incubated in 5%
CO2 at 37˚C for 2h, and the absorbance quantiﬁed at 490nm
in an automated microtiter plate reader (Tecan Sunrise, Jen-
cons, UK). Viability was calculated based on unexposed control
cells.
CYTOKINE EXPRESSION STUDIES
OKF6 cells were grown in 12 well tissue culture trays were
seeded and grown as described above and treated with TTO
and T-4-ol at 0.5MIC50 for 2min, washed then stimulated
with zymosan (50mg/ml). Media and zymosan controls were
also included. Supernatants were collected after 4 and 24h
and RNA extracted using TRIzol® according to the manufac-
turer’s instructions (Invitrogen, Paisley, Scotland). Total RNA
was treated with DNase I (Promega, Southampton, UK) at 37˚C
for 30min. RNA quality and quantity was assessed using a
NanoDrop™spectrophotometer ND-1000 (Labtech International
Ltd., Ringmer, East Sussex, UK), prior to cDNA production
using Superscript II Reverse Transcriptase (Invitrogen). qPCR
was then performed using an MxPro MX3000P Quantitative
PCRmachine(Stratagene,Amsterdam,Netherlands)withthefol-
lowing primers: IL-8 (F: 50-CAGAGACAGCAGAGCACACAA-30;
R: 50-TTAGCACTCCTTGGCAAAAC-30; 170bp), and the house-
keeping gene GAPDH (F: 50-GGTGGTGAAGACGCCAGT-30; R:
50-CAAGGCTGAGAACGGGAAG-30). Each duplicate PCR reac-
tion contained the following: 0.5ml of 1mg/ml of cDNA, 0.5ml
forward and reverse primer (10nmol),0.25ml ROX reference dye,
12.5ml SYBR® Green (Invitrogen), and 10.5ml dH2O. PCR reac-
tion conditions were as follows: 95˚C – 10min, 40 (94˚C – 30s,
58˚C–30s,72˚C–30s)and72˚C–10min.Analysiswasperformed
using the Mx3000P software (Stratagene) and gene expression
normalized to b-tublin gene according to the 2 DDCT method.
To assess IL-8 protein levels an ELISA was performed on retained
supernatants.ELISAkits(R&DSystems,Abingdon,UK)wereused
inaccordancewiththemanufacturer’sinstructions.Allassayswere
optimized and validated prior to use, with standards and samples
performed in at least duplicate.
STATISTICAL ANALYSIS
For assessing the statistical signiﬁcance of observed changes in
metabolic activity and biomass of C. albicans and IL-8 protein
levels in oral keratinocyte culture ﬂuids (data that conformed
to a near normal distribution) a one-way ANOVA with Bonfer-
roni multiple comparison post-test was performed. ANOVA and
post hoc tests were also used on natural log transformations (to
normalize) of proportional data for the analysis of IL-8 mRNA
abundance in these cells. p <0.05 was considered signiﬁcant. The
analyses were performed using GraphPad Prism version 4.0 for
Windows (GraphPad Software, CA, USA).
RESULTS
TTO AND DERIVATIVE COMPONENTS ARE EFFECTIVE AGAINST
CANDIDA ALBICANS BIOFILMS
The planktonic C. albicans isolates tested were susceptible to
TTO, T-4-ol, and a-terpineol, with an MIC50 of 0.5, 0.25, and
0.25%, respectively, and an MIC90 of 1.0, 0.5, and 0.5%, respec-
tively (Table 1). There was minimal variation in susceptibility as
determined by the concentration ranges for the 100 strains tested.
These three compounds also displayed potent activity against the
69strainscapableof formingbioﬁlms,withtheSMIC50 forT-4-ol
and a-terpineol showing no change when compared to median
effective planktonic concentration (SMFC50 D0.25%). However,
the concentration of TTO required to show a similar effect was
double that required to inhibit planktonic cells (SMFC50 D1%).
Allothercompoundstestedshowedrelativelypooractivityagainst
the isolates tested.
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Table 1 | Susceptibility proﬁle of Candida albicans to tea tree oil and derivative components.
Planktonic minimum inhibitory
concentrations (n D100)
Sessile minimum inhibitory
concentrations (n D69*)
MIC50 range (%) MIC50 (%) MIC90 (%) SMFC50 range (%) SMFC50 (%)** Sessile/planktonic
MIC50 ratio
TTO 0.125–1.0 0.5 1.0 1–4 1 2
T-4-ol 0.0625–0.5 0.25 0.5 <0.25–>1 0.25 1
a-Terpineol 0.125–0.5 0.25 0.5 <0.25–1 0.25 1
1,8-Cineole 0.5–>1 1 >1 <2–>2 2 2
Terpinolene 0.5–>1.0 >1 >1 2–>2 >2 >2
a-Terpinene 2–>2 >2 >2 4–>4 >4 >2
g-Terpinene 2–>2 >2 >2 4–>4 >4 >2
r-Cymene 2–>2 >2 >2 4–>4 >4 >2
*69 of the 100 strains tested were able to form bioﬁlms.
**Sessile minimum inhibitory concentration at which a 50% reduction in bioﬁlm metabolic activity was achieved.
The bioﬁlm rate of kill for the three most effective components
(TTO, T-4-ol, and a-terpineol) at 2SMIC50 was performed,
where time dependent killing was observed (Figure 1). TTO was
shown to reduce the viability of the bioﬁlmswithin 2min by 44%,
but after 5, 15, and 60min this had declined only slightly to 46,
56, and 65%, respectively. However, both T-4-ol and a-terpineol
displayed comparable and more effective killing,reducing the via-
bility rapidly after 2min by approximately 55%. This anti-bioﬁlm
activity remained,reducing bioﬁlm viability by approximately 61,
75, and 94% after 5, 15, and 60min, respectively. Both T-4-ol and
a-terpineol showed signiﬁcantly better activity than TTO only at
60min (p <0.001).
Inhibition of bioﬁlm formation was assessed for these three
compounds at 0.5 and 1MIC50 by assessing bioﬁlm biomass.
It was shown for all compounds that 1MIC50 was able to
inhibitbioﬁlmgrowtheffectivelywhentreatedat0,1,and2hpost
adhesion (8.5 12% biomass compared to control). At 4h post
adhesion,bywhichtimecellshadbegantoformhyphae,treatment
withTTO,T-4-ol,anda-terpineolfurthersuppressedbioﬁlmpro-
liferation by 71, 74, and 82% that of the control (Figure 2A). No
signiﬁcant differences were observed between the treatments at
eachtimepoint.Treatmentwith0.5MIC50 wasoveralllesseffec-
tive at inhibiting bioﬁlm growth most notably with TTO, which
displayed a time dependent reduction in inhibition, showing a
44% inhibition of cells treated at 4h (Figure 2B). Both T-4-ol
and a-terpineol were signiﬁcantly more effective against 1 and
2h cells (p <0.05), inhibiting bioﬁlm formation by >80%. How-
ever,this inhibition was reduced against the 4h cells (54 and 58%,
respectively).
TTO AND DERIVATIVE COMPONENTS ARE CELL MEMBRANE ACTIVE
Scanning electron microscopy analysis of TTO and T-4-ol treated
cells was performed. It was noted that compared to the control
(untreated) cells (Figure 3Ai), both compounds had ruptured
the cells, allowing the cell contents to leak out, giving a punc-
tured appearance (Figures 3Aii,iii). The cell damage was shown
to be more extensive for T-4-ol treated cells. Given this appear-
ance we hypothesized that cell membrane integrity had been
FIGURE 1 | Candida albicans bioﬁlm killing byTTO,T-4-ol, and
a-terpineol is time dependent. Standardized C. albicans (110
6 cells/ml)
were incubated in ﬂat-bottomed 96-well plates for 24h, washed in PBS, and
treated with 2SMIC50 at 2, 5, 10, 15, and 60min. Metabolic activity of
treated bioﬁlms was then quantiﬁed using the XTT assay by reading at
492nm in a microtiter plate reader (FluoStar Omega, BMG Labtech).Three
isolates were used for each assay, and this was performed on two
independent occasions in triplicate. **p <0.001. Error bars represent the
standard error of the mean.
compromised. We therefore undertook PI uptake experiments, as
previously reported (Sherry et al., 2012). For TTO, PI uptake was
shown to be relatively slow, with maximal ﬂuorescence obtained
at 30min (Figure3B). In comparison,for T-4-ol ﬂuorescence was
showntoincreaseinatimedependentmannerupto40min,twice
that of TTO, after which time this reached a plateau. These data
show similar kinetics to the time-kill data presented.
TTO AND TERPINEN-4-ol ARE BIOLOGICALLY ACTIVE AGAINST
MAMMALIAN CELLS
The effect of a short exposure (2min) of TTO and T-4-ol on
cellular toxicity was investigated. It was shown that TTO and T-4-
ol were toxic to both ﬁbroblast and epithelial cells at 1MIC50,
reducing the viability of PRF to approximately 12% and OKF6
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FIGURE 2 | Candida albicans bioﬁlm development is inhibited byTTO,
T-4-ol, and a-terpineol. Standardized C. albicans (110
6 cells/ml) were
added to a ﬂat-bottomed 96-well plate and treated with (A) 0.5 and (B)
1SMIC50 for 0, 1, 2, and 4h post incubation. Bioﬁlms were subsequently
allowed to develop for 24h. Resultant bioﬁlms were quantiﬁed using a
crystal violet assay read at 570nm in a microtiter plate reader (FluoStar
Omega, BMG Labtech). Four isolates were used for each assay, and this
was performed on two independent occasions in triplicate. *p <0.05. Error
bars represent the standard error of the mean.
cells to 35 and 15%, respectively (Figure 4A). At 0.5MIC50 T-
4-ol displayed no toxicity (98% viable) against PRF compared
with TTO (63% viable). Both 0.5 T-4-ol and 0.5 TTO were
non-toxic to OKF6 cells (>100% viable).
Giventhattheconcentrationof 1MIC50 iscytotoxic,allsub-
sequent work was performed with 0.5MIC50. Transcriptional
expression of IL-8 was assessed by qPCR, using zymosan as a
potent cell inﬂammatory agonist. Generally, greater IL-8 mRNA
levelswereobservedat4hcomparedto24h.TTOandT-4-olpre-
treatment of the cells had no effect on the induction of the IL-8
gene when compared to the control (Figure 4B). In zymosan-
stimulated cells pre-treatment with TTO did not reduce IL-8
expression signiﬁcantly at either 4 or 24h (p >0.05). Although
T-4-ol showed up to a twofold reduction in IL-8 expression in
cells at both 4 and 24h,though this reduction was not statistically
signiﬁcant (p >0.05).
Analysis of IL-8 protein levels after 4 and 24h stimulation
with zymosan showed that neither TTO or T-4-ol were able
FIGURE 3 |Tea tree oil andT-4-ol are cell membrane active. (A) Adherent
cells (3153A) were adhered for 2h onThermanox™coverslips and were (i)
untreated (control), or treated with (ii)TTO, or (iii)T-4-ol at 2MIC50 for
24h.These were then processed and viewed on an SEM. (B) C. albicans
(3153A) planktonic cells (510
7 cells/ml) were treated withTTO,T-4-ol, or
a-terpineol at a concentration of 2MIC50 for 10, 20, 30, 40, 50, and 60min.
The cells were washed by centrifugation, resuspended in PI (20mM in PBS),
and incubated for 15min at 37˚C.These were then transferred to a black
96-well plate for quantiﬁcation in a ﬂuorescent plate reader (Ex485/Em620).
Each assay was performed on at least two independent occasions in
triplicate. Error bars represent the standard error of the mean.
to signiﬁcantly affect IL-8 levels in culture ﬂuids (p >0.05) of
untreatedandzymosan-stimulatedoralkeratinocytes(datashown
for zymosan only). Nevertheless, a signiﬁcant (50%) reduction in
IL-8 expression was observed in culture ﬂuids of TTO treated
zymosan-stimulated cells (p <0.05), and a modest reduction of
approximately14%of IL-8wasnotedforT-4-oltreatedzymosan-
stimulated cells (Figure 4C). These compounds had no effect on
the IL-8 ELISA (data not shown).
DISCUSSION
Increasing use of conventional antifungal agents, such as azoles,
in parallel with larger groups of susceptible individuals (aging
populationandmorecommonimmunosuppressivetherapies)has
resulted in the emergence of multidrug-resistant Candida strains
(SanglardandOdds,2002;Akins,2005;Cannonetal.,2007;Niimi
et al.,2010). Non-compliance due to toxic side-effects and palata-
bility may also exacerbate this escalating trend. Consequently,
there is a demand for novel therapies to manage these infections.
Ourcurrentandpreviousdatainvestigatingtheeffectof TTOona
wide variety of yeast species clearly demonstrate that it is effective
against C. albicans planktonic and bioﬁlm cells (Bagg et al.,2006).
Given the complex chemical composition of TTO we aimed to
investigate key individual components to assess speciﬁc activities.
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FIGURE 4 |Tea tree oil andT-4-ol are biologically active against
mammalian cells. (A) PR ﬁbroblast and OKF6 epithelial cells were grown
until 90–100% conﬂuent.These were exposed to 0.5 and 1MIC50 of each
compound for 2min. Cell viability was assessed using an XTT assay after
incubation in 5% CO2 at 37˚C for 2h. Viability was calculated based on
unexposed control cells. For cytokine studies OKF6 cells were grown in 12
well tissue culture trays treated withTTO andT-4-ol at 0.5MIC50 for 2min,
washed then stimulated with zymosan (50mg/ml). Cells were processed for
(B) qPCR analysis and (C) supernatant was processed for protein analysis
of IL-8. Each assay was performed on three independent occasions in
triplicate. *p <0.05. Error bars represent the standard error of the mean.
T-4-ol and a-terpineol exhibited the greatest and comparable
antifungal activity against both planktonic and sessile cells,which
hasbeenconﬁrmedfromreportselsewhere(Hammeretal.,2003a;
Mondelloetal.,2006;Terzietal.,2007).Moreover,time-killstudies
showedarapidandsustainedlevelof activityof bothcompounds,
signiﬁcantlysuperiortoTTOat2MIC90after60min.Thissupe-
rior activity was less evident during the early bioﬁlm inhibition
studies (0–2h), however, at 4h TTO showed a signiﬁcant decline
initsabilitytoinhibitbioﬁlmgrowth.BothT-4-olanda-terpineol
have hydroxyl groups in their chemical structures, making them
moderately water-soluble. This allows them to diffuse through
water, enter, and destabilize cell membranes, resulting in osmotic
shock (Straede et al., 2007). This was evident from analysis of
cell membrane integrity using a PI uptake assay and microscopic
examination by SEM.
T-4-ol and a-terpineol both showed excellent activity, but the
remainder of the studies compared TTO with T-4-ol, primarily
because of the high bioavailability of the latter within TTO and
itsoverallantifungalproﬁle(Carsonetal.,2006).Cytotoxicitywas
observed at MIC50 levels for both TTO and T-4-ol, whereas at
0.5MIC50 (concentrations able to inhibit C. albicans growth)
OKF6 cells remained viable. Previous reports have demonstrated
varying levels of cytotoxicity to primary ﬁbroblasts and primary
epithelial cells, with a 1 h exposure to 0.03%TTO shown to be
toxic (Soderberg et al., 1996). Further reports indicated that a 4 h
exposureto0.28%TTOwasrequiredtoinhibittheHeLaepithelial
cell line (Hayes et al., 1997). In addition, it was shown previously
thatTTOwashighlytoxictomonocytesandneutrophils,butafter
a prolonged 20h exposure (Hart et al., 2000). The relevance of
this length of exposure is difﬁcult to interpret. Collectively, these
studieshighlighttheimportanceof thecelllinebeingtestedandin
what context. Given that our primary interests lay in developing a
mouthwash to prevent candidal growth as opposed to treating an
activeinfection,a2minexposureofsub-inhibitoryconcentrations
was deemed optimal.
These data were used to assess the impact of TTO-based
compounds on inﬂammation, using IL-8 as a biomarker. Both
transcriptional and protein analysis showed that IL-8 was regu-
lated by both compounds, with TTO showing protein reduction
of approximately 50% 24h post treatment, whereas T-4-ol only
caused a 14% reduction. However, at 4h post treatment T-4-ol
inhibited IL-8 protein production by 53% opposed to 16% for
TTO, although neither was signiﬁcant. The differences observed
may be accounted for by the quantitative composition of TTO,
which contains approximately 40% T-4-ol. A previous study of
LPS stimulated monocytes demonstrated a signiﬁcant IL-8 sup-
pression by 0.052% T-4-ol after 40h (Hart et al., 2000). The
discordance with our data can be explained through differences
in concentration and exposure time. Irrespective, both studies
indicate that these molecules have the potential capacity to sup-
pressinﬂammatorymediators,whicharecommonwithintheoral
cavity of OPC sufferers. Indeed, there is in vivo evidence to sup-
port this. Several murine studies have shown inhibitory effects on
inﬂammatory processes,including reduced contact hypersensitiv-
ity(Brandetal.,2002a),reducedhistamine-inducededema(Brand
et al., 2002b), and blocking of zymosan-induced inﬂammation
by inhaled TTO (Golab and Skwarlo-Sonta, 2007). In humans,
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nickel-induced contact hypersensitivity has been reduced by the
topical application of 100% TTO (Pearce et al., 2005). Both TTO
(Koh et al., 2002) and T-4-ol (Khalil et al., 2004) have also been
shown to reduce histamine-induced weal and ﬂare reaction in
human skin. Conversely, other studies have implicated TTO as
being pro-inﬂammatory (de Groot and Weyland, 1992; Ruther-
ford et al., 2007). Given the apparent contradictory reports in the
literature it seems prudent to focus on utilizing the most biologi-
cally active and abundant compound from TTO, i.e., T-4-ol. This
will enable investigators to determine accurately the medicinal
beneﬁts of pure T-4-ol and exclude deleterious effects caused by
the other terpenes that comprise TTO.
In summary, these studies have added to the body of in vitro
evidence indicating that TTO and some of its individual com-
ponents, speciﬁcally T-4-ol, exhibit strong antimicrobial efﬁcacy
against fungal bioﬁlms. Furthermore, this has also demonstrated
a potential bioﬁlm inhibiting activity, suggesting that this agent
may be suitable for use in prophylactic oral hygiene products such
as mouth rinses and denture cleansers, as well as treatment for
establishedOPCinfections.Theuseof T-4-ol,asinglecomponent
from TTO,has advantages over the complete essential oil in terms
of product safety and consistency. Oral candidosis is a continuing
problem for cancer patients, as well as other groups of immuno-
compromised hosts. In the face of increasing resistance to azoles
and other established antifungal drugs, the need for novel pre-
ventive and therapeutic agents has never been greater. The weight
of laboratory data that has now accumulated and the anecdo-
tal reports of clinical efﬁcacy suggest that clinical trials of TTO
components, particularly T-4-ol, would be merited.
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